The Delaware BioScience Association (Delaware Bio) announced the new life science companies selected to participate in a pitch competition during a first-ever industry conference on May 11.
Delaware’s DNA: 2023 Life Science Conference will explore the industry’s most critical and timely issues. This will include showcasing research and new companies.
The eight young firms (founded in the last five years) have been selected from a pool of applicants to present during the “Most Promising New Company” pitch competition, during which all conference attendees will be eligible to vote on the companies with the most exciting story and prospects:
• BioCurie
• Cellergy Pharma
• CorriXR Therapeutics, Inc.
• Cosmos Pharmaceuticals LLC
• Hartlon LLC
• Innovative Precision Health
• Nitro Biosciences
• Radiolife
Each company will have three minutes to present its technology, products, or services, with the top three vote-getters awarded a cash prize ($2,500 for first prize and $1000 each for the two runners-up).
“These exciting new companies represent the full breadth and dynamism of the greater Delaware region’s life science ecosystem,” said Michael Fleming, president of Delaware Bio. “Presenting at Delaware’s DNA will be a hugely valuable opportunity for these founders to share their story with the most important and influential industry audience ever assembled in our state.”
Delaware’s DNA: 2023 Life Science Conference headliners include Delaware Governor John Carney, Incyte CEO Hervé Hoppenot, Biotechnology Innovation Organization (BIO) CEO Rachel King, University of Delaware president Dennis Assanis, Aisling Capital founder Dennis Purcell, JP Morgan managing director Sophie Jones, Bernstein senior analyst Will Pickering, Jonathan Franca-Koh of National Institutes of Health/National Cancer Institute, National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) Director Kelvin Lee, Prelude Therapeutics CEO Kris Vaddi and Eric Kmiec, Director of the Gene Editing Institute, and founder of CorriXR Therapeutics.
Conference program
• An inside perspective on the state of the industry from leading industry analysts and investors
• Key issues in economic and workforce development
• The regional potential for advanced and biopharmaceutical manufacturing
• Advances and innovations in cancer research and treatment
Another element of Delaware DNA will be local researchers’ poster presentations on cutting-edge science. Throughout the conference, students and faculty of area educational and biomedical research institutions will be on hand to share and discuss their compelling work with attendees.
Partnering Through the App
The conference app also includes a partnering tool allowing attendees to schedule one-on-one meetings between companies, researchers, investors and other businesses. Meetings will be hosted on the platform virtually the following Thursday, May 18.
Promising companies
BioCurie – BioCurie is developing an AI software platform that will revolutionize cell and gene therapy (CGT) production to make these lifesaving therapies faster, better, and cheaper.
Cellergy Pharma – Cellergy Pharma develops novel immunotherapies for the treatment of severe allergic diseases.
CorriXR Therapeutics, Inc. – CorriXR Therapeutics, the first spin-out of ChristianaCare’s Gene Editing Institute, has developed an IP-protected gene editing platform that reverses cancer drug resistance in tumor cells, but not in surrounding healthy cells.
Cosmos Pharmaceuticals LLC – Cosmos is a medical device company focused on the relationship between medication adherence and patient outcomes. FortisKap, a smart pill cap, records adherence data in real time to improve patient well being.
Hartlon LLC – Hartlon’s lead product is a novel resorbable vascular stent that is designed to salvage limbs that are at risk of amputation by restoring blood flow below the knee (BTK).
Innovative Precision Health – Innovative Precision Health (IPH) is a healthcare technology company that provides comprehensive solutions for precision health. Our platform integrates data collection, analysis, and interpretation and is implemented and validated nationwide.
Nitro Biosciences – Nitro Biosciences is a startup company from the University of Delaware developing a live bacterial vaccine platform to target diseases/antigens normally hidden from the immune system.
Radiolife – Proprietary technology that combines radio frequency signatures with AI to enable the rapid and cost-effective detection of viruses, bacteria, and cancer cells.
Sponsors
• ABS
• ANP Technologies
• Avantor
• Bancroft Construction
• Biotechnology Innovation Organization
• BioTek ReMEDys
• Chestnut Run Innovation & Science Park
• Choice Med Waste
• Comprehensive Cell Solutions
• Delaware Biotechnology Institute
• Delaware Business Times
• Delaware Prosperity Partnership
• Delaware Technology Park
• Facility Logix
• Incyte
• Innovation Space
• LabWare
• McCarter & English
• Nemours
• NIIMBL
• Prelude Therapeutics
• QPS Holdings
• Scheer Partners
• University of Delaware
• The Whiting-Turner Contracting Company
For conference agenda details, information on sponsorship, and to purchase tickets, go to: delawarebio.org/page/delawares-dna
